By: IPP Bureau
Last updated : June 24, 2024 6:29 pm
The company will work closely with the USFDA and is committed to address these comprehensively within stipulated time
USFDA has conducted an inspection at the Cipla Ltd's manufacturing facility in Goa, India from 10th - 21st June 2024.
On conclusion of the inspection, the company received 6 (six) inspectional observations in Form 483. The company will work closely with the USFDA and is committed to address these comprehensively within stipulated time.